Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
38K characters. Original on sec.gov ·
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ABOUT STRYKER
Stryker Corporation ("we" or the "Company") is a global leader in
medical technologies and, together with our customers, we are
driven to make healthcare better. We offer innovative products
and services in MedSurg, Neurotechnology, and Orthopaedics
that help improve patient and healthcare outcomes. Alongside
our customers around the world, we impact more than 150 million
patients annually. Our goal is to achieve sales growth at the high-
end of the medical technology (MedTech) industry and maintain
our long-term capital allocation strategy that prioritizes: (1)
Acquisitions, (2) Dividends and (3) Share repurchases.
In the first quarter 2026 we announced a change in our
organizational structure. Our new Ortho Tech business combines
the orthopaedic instruments portfolio from our Instruments
business with our Mako and enabling technologies portfolio from
our Other Orthopaedics business. By bringing Mako, power tools,
cutting accessories, enabling technologies and the teams behind
these products together under one business, we are simplifying
the customer experience and striving to increase our speed to
market through focused innovation.
Following this reorganization we will continue to have two
business segments - (i) MedSurg and Neurotechnology and (ii)
Orthopaedics, each of which comprise a reportable segment. All
historical financial segment information has been recast to
conform to this new presentation.
MedSurg and Neurotechnology products include surgical
equipment, patient and caregiver safety technologies, and a
comprehensive line of products for traditional brain and open
skull-based surgical procedures orthobiologic and biosurgery
products, including synthetic bone grafts and vertebral
augmentation (Instruments), endoscopic and communications
systems (Endoscopy), patient handling, emergency medical
equipment, intensive care disposable products, clinical
communication and artificial intelligence-assisted virtual care
platform technology (Medical), and minimally invasive products
for the treatment of acute ischemic and hemorrhagic stroke and
venous thromboembolism (Vascular). Orthopaedics products
include implants and surgical equipment such as navigation
systems and robotics used in total joint replacements, such as
hip, knee and shoulder, ankle and trauma and extremities
surgeries. We bring patients and physicians advanced implant
designs and specialized instrumentation that make orthopaedic
surgery and recovery simpler, faster and more effective. We
support surgeons with technologies, products and services they
need to support each patient’s clinical challenge.
Macroeconomic Environment
In 2025 the United States government announced new tariffs on
goods imported into the United States from dozens of countries,
including China and the European Union member states. In 2026
the United States Supreme Court issued a ruling in Learning
Resources, Inc. v. Trump striking down certain tariffs previously
imposed under the International Emergency Economic Powers
Act. While this ruling may lead to potential refunds for tariffs paid
during 2025, and the United States government subsequently
announced a process for seeking such refunds, the availability,
timing, and amount of such refunds remain uncertain and subject
to further legal and administrative developments. Following this
decision the United States administration announced the
invocation of alternative authorities, including Section 122 of the
Trade Act of 1974, to impose new tariffs on imports. These further
actions may increase costs and impact our operational results.
We continue to monitor and evaluate the situation. The overall
macroeconomic and geopolitical environment, including tariffs or
changes in trade policies, slower economic growth or recession,
market volatility and inflation, and uncertainty regarding all of the
foregoing, pose risks that could impact our business and results
of operations. For more information about these risks, see Item
1A. "Risk Factors" in our Annual Report on Form 10-K for 2025.
Overview of the Three Months
In the three months 2026 we achieved sales growth of 2.6% from
- Excluding the impact of acquisitions and divestitures, sales
grew 1.0% in constant currency. We reported operating income
margin of 15.5%, net earnings of $745 and net earnings per
diluted share of $1.93. Excluding the impact of certain items,
adjusted operating income margin(1) contracted by 180 basis
points to 21.1%, with adjusted net earnings(1) of $1,004 and
adjusted net earnings per diluted share(1) of $2.60, a decrease of
8.5% from 2025.
Recent Developments
In the first quarter 2026 we identified a cybersecurity incident
which caused disruptions to our business operations. We worked
diligently, together with third-party experts and law enforcement,
to contain and neutralize the impact of the incident and restore
operations. Our investigation of the incident remains ongoing. For
more information about risks relating to the impact of the
cybersecurity incident to our business, financial condition and
results of operations, see Item 1A. “Risk Factors” in Part II of this
Form 10-Q.
(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-
GAAP financial measures used in this report and a reconciliation to the
most directly comparable GAAP financial measure.
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 12 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
| CONSOLIDATED RESULTS OF OPERATIONS | |||||||||
| Three Months | |||||||||
| Percent Net Sales | Percentage | ||||||||
| 2026 | 2025 | 2026 | 2025 | Change | |||||
| Net sales | $6,020 | $5,866 | 100.0% | 100.0% | 2.6% | ||||
| Gross profit | 3,810 | 3,744 | 63.3 | 63.8 | 1.8 | ||||
| Research, development and engineering expenses | 413 | 405 | 6.9 | 6.9 | 2.0 | ||||
| Selling, general and administrative expenses | 2,281 | 2,300 | 37.9 | 39.2 | (0.8) | ||||
| Amortization of intangible assets | 180 | 167 | 3.0 | 2.8 | 7.8 | ||||
| Goodwill and other impairments | — | 35 | — | 0.6 | nm | ||||
| Interest expense | (148) | (137) | (2.5) | (2.3) | 8.0 | ||||
| Other income | 62 | 64 | 1.0 | 1.1 | (3.1) | ||||
| Income taxes | 105 | 110 | nm | nm | (4.5) | ||||
| Net earnings | $745 | $654 | 12.4% | 11.1% | 13.9% | ||||
| Net earnings per diluted share | $1.93 | $1.69 | 14.2% | ||||||
| Adjusted net earnings per diluted share**(1)** | $2.60 | $2.84 | (8.5)% |
nm - not meaningful
| Geographic and Segment Net Sales | ||||||
| Three Months | ||||||
| Percentage Change | ||||||
| 2026 | 2025 | As Reported | Constant Currency | |||
| Geographic: | ||||||
| United States | $4,476 | $4,440 | 0.8% | 0.8% | ||
| International | 1,544 | 1,426 | 8.3 | 1.5 | ||
| Total | $6,020 | $5,866 | 2.6% | 1.0% | ||
| Segment: | ||||||
| MedSurg and Neurotechnology | $3,207 | $3,056 | 5.0% | 3.6% | ||
| Orthopaedics | 2,813 | 2,810 | 0.1 | (1.8) | ||
| Total | $6,020 | $5,866 | 2.6% | 1.0% |
| Supplemental Net Sales Growth Information | |||||||||||
| Three Months | |||||||||||
| Percentage Change | |||||||||||
| United States | International | ||||||||||
| 2026 | 2025 | As Reported | Constant Currency | As Reported | As Reported | Constant Currency | |||||
| MedSurg and Neurotechnology: | |||||||||||
| Instruments | $920 | $838 | 9.9% | 8.7% | 9.1% | 14.0% | 7.0% | ||||
| Endoscopy | 868 | 867 | 0.1 | (1.0) | (1.2) | 6.0 | — | ||||
| Medical | 902 | 945 | (4.6) | (5.6) | (6.9) | 8.3 | 1.1 | ||||
| Vascular | 517 | 406 | 27.5 | 24.0 | 37.9 | 17.0 | 10.5 | ||||
| $3,207 | $3,056 | 5.0% | 3.6% | 3.2% | 11.7% | 5.1% | |||||
| Orthopaedics: | |||||||||||
| Knees | $670 | $639 | 4.7% | 2.8% | 1.4% | 13.5% | 6.1% | ||||
| Hips | 460 | 443 | 3.7 | 1.2 | 2.3 | 6.0 | (0.3) | ||||
| Trauma and Extremities | 1,035 | 945 | 9.5 | 7.4 | 7.6 | 15.3 | 6.8 | ||||
| Ortho Tech | 646 | 617 | 4.8 | 3.2 | 2.0 | 12.9 | 6.5 | ||||
| $2,811 | $2,644 | 6.3% | 4.3% | 4.0% | 12.2% | 4.9% | |||||
| Spinal Implants | 2 | 166 | (98.9) | (99.0) | (100.0) | (96.2) | (96.6) | ||||
| $2,813 | $2,810 | 0.1% | (1.8)% | (2.0)% | 5.5% | (1.3)% | |||||
| Total | $6,020 | $5,866 | 2.6% | 1.0% | 0.8% | 8.3% | 1.5% |
Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the
orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and
the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics was combined with the remaining
Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $489
and $484 and Other Orthopaedics of $157 and $133. Instruments includes sales related to Neuro Cranial of $606 and $563 and
Enabling Technologies of $26 and $29 for the three months 2026 and 2025. We have reflected these changes in all historical periods
presented.
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 13 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
Consolidated Net Sales
Consolidated net sales increased 2.6% in the three months 2026
as reported and 1.0% in constant currency, as foreign currency
exchange rates positively impacted net sales by 1.6%. Excluding
the 1.4% impact of acquisitions and divestitures, net sales in
constant currency increased by 2.1% from increased unit volume
and 0.3% due to higher prices. The unit volume increase was due
to higher product shipments across most MedSurg and
Neurotechnology businesses and all Orthopaedics businesses.
MedSurg and Neurotechnology Net Sales
MedSurg and Neurotechnology net sales increased 5.0% in the
three months 2026 as reported and 3.6% in constant currency, as
foreign currency exchange rates positively impacted net sales by
1.4%. Excluding the 2.7% impact of acquisitions and divestitures,
net sales in constant currency increased by 0.3% from increased
unit volume and 0.6% from higher prices. The unit volume
increase was due to higher shipments across the Instruments
and Vascular businesses.
Orthopaedics Net Sales
Orthopaedics net sales increased 0.1% in the three months 2026
as reported but decreased 1.8% in constant currency, as foreign
currency exchange rates positively impacted net sales by 1.9%.
Excluding the 5.9% impact of acquisitions and divestitures, net
sales in constant currency increased 4.1% from increased unit
volume. The unit volume increase was due to higher shipments
across all Orthopaedics businesses.
Gross Profit
Gross profit was $3,810 and $3,744 in the three months 2026
and 2025. The key components of the change were:
| Gross Profit Percent Net Sales | |
| Three Months 2025 | 63.8% |
| Sales pricing | 10 bps |
| Volume and mix | 10 bps |
| Manufacturing and supply chain costs | (200) bps |
| Structural optimization and other special charges | 70 bps |
| Inventory stepped up to fair value | 60 bps |
| Three Months 2026 | 63.3% |
Gross profit as a percentage of net sales in the three months
2026 decreased to 63.3% from 63.8% in 2025 driven by higher
manufacturing and supply chain costs primarily due to idle
production time related to the cybersecurity incident.
Research, Development and Engineering Expenses
Research, development and engineering expenses increased $8
or 2.0% in the three months 2026. Expenses as a percentage of
net sales of 6.9% in the three months 2026 remained flat with
Selling, General and Administrative Expenses
Selling, general and administrative expenses decreased $19 or
0.8% in the three months 2026. As a percentage of net sales,
expenses decreased to 37.9% from 39.2% in 2025, primarily due
to continued spend discipline and lower acquisition and
integration-related charges. Expenses in the three months 2025
included a charge of $139 for share-based awards for Inari
employees that vested upon our acquisition.
Amortization of Intangible Assets
Amortization of intangible assets was $180 and $167 in the three
months 2026 and 2025. Refer to Note 7 to our Consolidated
Financial Statements for further information.
Goodwill and other impairments
Goodwill and other impairments was $35 in the three months
Operating Income
Operating income was $936 and $837 in the three months 2026
and 2025. Operating income as a percentage of net sales in the
three months 2026 increased to 15.5% from 14.3% in 2025.
Refer to the discussion above for the primary drivers of the
change.
MedSurg and Neurotechnology operating income as a
percentage of net sales decreased to 21.8% in the three months
2026 from 24.8% in 2025. Orthopaedics operating income as a
percentage of net sales decreased to 30.1% in the three months
2026 from 30.4% in 2025. The key components of the change
were:
| Operating Income Percent Net Sales | ||
| MedSurg and Neurotechnology | Orthopaedics | |
| Three Months 2025 | 24.8% | 30.4% |
| Sales pricing | 20 bps | 0 bps |
| Volume | 20 bps | (10) bps |
| Manufacturing and supply chain costs | (220) bps | (190) bps |
| Research, development and engineering expenses | (40) bps | 40 bps |
| Selling, general and administrative expenses | (80) bps | 130 bps |
| Three Months 2026 | 21.8% | 30.1% |
The decrease in MedSurg and Neurotechnology operating
income as a percentage of net sales for the three months was
primarily driven by higher manufacturing and supply chain costs
due to idle production time related to the cybersecurity incident,
higher selling, general and administrative expenses, and higher
research, development and engineering expenses partially offset
by higher unit volumes and prices.
The decrease in Orthopaedics operating income as a percentage
of net sales for the three months was primarily driven by higher
manufacturing and supply chain costs due to idle production time
related to the cybersecurity incident and lower unit volumes
partially offset by lower selling, general and administrative
expenses and research, development and engineering expenses.
Interest Expense
Interest expense was $148 and $137 in the three months 2026
and 2025. The increase in interest expense in the three months
2026 from 2025 was primarily due to 2025 debt issuances.
Other Income
Other income was $62 and $64 in the three months 2026 and
- The decrease in other income in the three months 2026
from 2025 was primarily due to lower interest income in 2026.
Income Taxes
Our effective tax rates were 12.4% and 14.4% in the three
months 2026 and 2025. The effective tax rates for the three
months 2026 and 2025 reflect the continued lower effective
income tax rates as a result of our European operations and
certain discrete tax items.
Our future results of operations could be affected by changes in
the effective tax rate as a result of changes in tax laws,
regulations and judicial rulings. We are continuing to evaluate the
impact of tax reform in the countries in which we operate as new
guidance is published and new regulations are adopted.
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 14 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
Net Earnings
Net earnings increased to $745 or $1.93 per diluted share in the
three months 2026 from $654 or $1.69 per diluted share in 2025.
Refer to the discussion above for the primary drivers of the
change.
Non-GAAP Financial Measures
We supplement the reporting of our financial information
determined under accounting principles generally accepted in the
United States (GAAP) with certain non-GAAP financial measures,
including percentage sales growth in constant currency;
percentage organic sales growth; adjusted gross profit; adjusted
selling, general and administrative expenses; adjusted research,
development and engineering expenses; adjusted operating
income; adjusted other income (expense), net; adjusted income
taxes; adjusted effective income tax rate; adjusted net earnings;
and adjusted net earnings per diluted share (Diluted EPS). We
believe these non-GAAP financial measures provide meaningful
information to assist investors and shareholders in understanding
our financial results and assessing our prospects for future
performance. Management believes percentage sales growth in
constant currency and the other adjusted measures described
above are important indicators of our operations because they
exclude items that may not be indicative of or are unrelated to our
core operating results and provide a baseline for analyzing trends
in our underlying businesses. Management uses these non-
GAAP financial measures for reviewing the operating results of
reportable business segments and analyzing potential future
business trends in connection with our budget process and bases
certain management incentive compensation on these non-GAAP
financial measures. To measure percentage sales growth in
constant currency, we remove the impact of changes in foreign
currency exchange rates that affect the comparability and trend
of sales. Percentage sales growth in constant currency is
calculated by translating current and prior year results at the
same foreign currency exchange rate. To measure percentage
organic sales growth, we remove the impact of changes in
foreign currency exchange rates, acquisitions and divestitures,
which affect the comparability and trend of sales. Percentage
organic sales growth is calculated by translating current year and
prior year results at the same foreign currency exchange rates
excluding the impact of acquisitions and divestitures. To measure
earnings performance on a consistent and comparable basis, we
exclude certain items that affect the comparability of operating
results and the trend of earnings. The income tax effect of each
adjustment was determined based on the tax effect of the
jurisdiction in which the related pre-tax adjustment was recorded.
These adjustments are irregular in timing and may not be
indicative of our past and future performance. The following are
examples of the types of adjustments that may be included in a
period:
1.Acquisition and integration-related costs. Costs related to
integrating recently acquired businesses (e.g., costs
associated with the termination of sales relationships,
employee retention and workforce reductions, manufacturing
integration costs and other integration-related activities),
changes in the fair value of contingent consideration,
amortization of inventory stepped-up to fair value, specific
costs (e.g., deal costs and costs associated with legal entity
rationalization) related to the consummation of the
acquisition process and legal entity rationalization and
acquisition-related tax items.
2.Amortization of purchased intangible assets. Periodic
amortization expense related to purchased intangible assets.
3.Structural optimization and other special charges. Costs
associated with employee retention and workforce
reductions, the closure or transfer of manufacturing and
other facilities (e.g., site closure costs, contract termination
costs and redundant employee costs during the work
transfers), product line exits (primarily inventory, long-lived
asset and specifically-identified intangible asset write-offs),
certain long-lived and intangible asset write-offs and
impairments and other charges.
4.Medical device regulations. Costs specific to updating our
quality system, product labeling, asset write-offs and product
remanufacturing to comply with the new medical device
reporting regulations and other requirements of the
European Union.
5.Recall-related matters. Changes in our best estimate of the
probable loss, or the minimum of the range of probable
losses when a best estimate within a range is not known, to
resolve the Rejuvenate, LFIT V40, Wright legacy hip
products and other product recalls.
6.Regulatory and legal matters. Changes in our best estimate
of the probable loss, or the minimum of the range of
probable losses when a best estimate within a range is not
known, to resolve certain regulatory or other legal matters
and the amount of favorable awards from settlements.
7.Tax matters. Impact of accounting for certain significant and
discrete tax items.
Because non-GAAP financial measures are not standardized, it
may not be possible to compare these financial measures with
other companies' non-GAAP financial measures having the same
or similar names. These adjusted financial measures should not
be considered in isolation or as a substitute for reported sales
growth, gross profit, selling, general and administrative expenses,
research, development and engineering expenses, operating
income, other income (expense), net, income taxes, effective
income tax rate, net earnings and net earnings per diluted share,
the most directly comparable GAAP financial measures. These
non-GAAP financial measures are an additional way of viewing
aspects of our operations when viewed with our GAAP results
and the reconciliations to corresponding GAAP financial
measures at the end of the discussion of Consolidated Results of
Operations below. We strongly encourage investors and
shareholders to review our financial statements and publicly-filed
reports in their entirety and not to rely on any single financial
measure.
The weighted-average diluted shares outstanding used in the
calculation of adjusted net earnings per diluted share are the
same as those used in the calculation of reported net earnings
per diluted share for the respective period.
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 15 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
| Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures | |||||||||
| Three Months 2026 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other Income (Expense), Net | Income Taxes | Net Earnings | Effective Tax Rate | Diluted EPS |
| Reported | $3,810 | $2,281 | $413 | $936 | $(86) | $105 | $745 | 12.4% | $1.93 |
| Reported percent net sales | 63.3% | 37.9% | 6.9% | 15.5% | (1.4)% | nm | 12.4% | ||
| Acquisition and integration-related costs: | |||||||||
| Inventory stepped-up to fair value | — | — | — | — | — | — | — | — | — |
| Other acquisition and integration-related (a) | 2 | (13) | (4) | 19 | — | 4 | 15 | 0.1 | 0.04 |
| Amortization of purchased intangible assets | — | — | — | 180 | — | 30 | 150 | 0.6 | 0.38 |
| Structural optimization and other special charges (b) | 14 | (104) | — | 118 | (11) | 25 | 82 | 1.1 | 0.21 |
| Goodwill and other impairments (c) | — | — | — | — | — | — | — | — | — |
| Medical device regulations (d) | — | — | (5) | 5 | — | 1 | 4 | — | 0.01 |
| Recall-related matters (e) | 1 | (9) | — | 10 | — | 2 | 8 | 0.1 | 0.02 |
| Regulatory and legal matters (f) | — | (3) | — | 3 | — | 1 | 2 | — | 0.01 |
| Tax matters (g) | — | — | — | — | — | 2 | (2) | 0.2 | — |
| Adjusted | $3,827 | $2,152 | $404 | $1,271 | $(97) | $170 | $1,004 | 14.5% | $2.60 |
| Adjusted percent net sales | 63.6% | 35.8% | 6.7% | 21.1% | (1.6)% | nm | 16.7% |
| Three Months 2025 | Gross Profit | Selling, General & Administrative Expenses | Research, Development & Engineering Expenses | Operating Income | Other Income (Expense), Net | Income Taxes | Net Earnings | Effective Tax Rate | Diluted EPS |
| Reported | $3,744 | $2,300 | $405 | $837 | $(73) | $110 | $654 | 14.4% | $1.69 |
| Reported percent net sales | 63.8% | 39.2% | 6.9% | 14.3% | (1.2)% | nm | 11.1% | ||
| Acquisition and integration-related costs: | |||||||||
| Inventory stepped-up to fair value | 34 | — | — | 34 | — | 8 | 26 | 0.5 | 0.07 |
| Other acquisition and integration-related (a) | 13 | (171) | (1) | 185 | — | 6 | 179 | (2.5) | 0.47 |
| Amortization of purchased intangible assets | — | — | — | 167 | — | 34 | 133 | 1.4 | 0.35 |
| Structural optimization and other special charges (b) | 22 | (19) | — | 41 | — | 14 | 27 | 1.0 | 0.07 |
| Goodwill and other impairments (c) | — | — | — | 35 | — | 9 | 26 | 0.7 | 0.06 |
| Medical device regulations (d) | 1 | — | (11) | 12 | — | 3 | 9 | 0.1 | 0.02 |
| Recall-related matters (e) | 31 | (2) | — | 33 | — | 8 | 25 | 0.5 | 0.06 |
| Regulatory and legal matters (f) | — | — | — | — | — | 1 | (1) | — | — |
| Tax matters (g) | — | — | — | — | — | (19) | 19 | (2.4) | 0.05 |
| Adjusted | $3,845 | $2,108 | $393 | $1,344 | $(73) | $174 | $1,097 | 13.7% | $2.84 |
| Adjusted percent net sales | 65.5% | 35.9% | 6.7% | 22.9% | (1.2)% | nm | 18.7% |
nm - not meaningful
(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:
| Three Months | |||
| 2026 | 2025 | ||
| Employee retention and workforce reductions | $3 | $16 | |
| Changes in the fair value of contingent consideration | 3 | (2) | |
| Manufacturing integration costs | 5 | 4 | |
| Stock compensation payments upon a change in control | — | 139 | |
| Other integration-related activities | 8 | 28 | |
| Adjustments to Operating Income | $19 | $185 | |
| Other income taxes related to acquisition and integration-related costs | 4 | 6 | |
| Adjustments to Income Taxes | $4 | $6 | |
| Adjustments to Net Earnings | $15 | $179 |
(b) Structural optimization and other special charges represent the costs associated with:
| Three Months | |||
| 2026 | 2025 | ||
| Employee retention and workforce reductions | $7 | $32 | |
| Closure/transfer of manufacturing and other facilities | 5 | 5 | |
| Product line exits | 2 | 3 | |
| Termination of sales relationships in certain countries | 81 | — | |
| Other charges | 23 | 1 | |
| Adjustments to Operating Income | $118 | $41 | |
| Adjustments to Other Income (Expense), Net | $(11) | $— | |
| Adjustments to Income Taxes | $25 | $14 | |
| Adjustments to Net Earnings | $82 | $27 |
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 16 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
(c) Goodwill and other impairments represent the costs associated with:
| Three Months | |||
| 2026 | 2025 | ||
| Certain long-lived and intangible asset write-offs and impairments | $— | $34 | |
| Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs) | — | 1 | |
| Adjustments to Operating Income | $— | $35 | |
| Adjustments to Income Taxes | $— | $9 | |
| Adjustments to Net Earnings | $— | $26 |
(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device
reporting regulations and other requirements of the new medical device regulations in the European Union.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to
resolve certain recall-related matters.
(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to
resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:
| Three Months | |||
| 2026 | 2025 | ||
| Adjustments related to the transfer of certain intellectual properties between tax jurisdictions | $(20) | $(47) | |
| Other tax matters | 22 | 28 | |
| Adjustments to Income Taxes | $2 | $(19) | |
| Adjustments to Other Income (Expense), Net | $— | $— | |
| Adjustments to Net Earnings | $(2) | $19 |
FINANCIAL CONDITION AND LIQUIDITY
| Three Months | |||
| Net cash provided by (used in): | 2026 | 2025 | |
| Operating activities | $581 | $250 | |
| Investing activities | (185) | (4,136) | |
| Financing activities | (1,510) | 2,534 | |
| Effect of exchange rate changes | (19) | 20 | |
| Change in cash and cash equivalents | $(1,133) | $(1,332) |
Operating Activities
Cash provided by operating activities was $581 and $250 in the
three months 2026 and 2025. The increase was primarily due to
changes in working capital accounts.
Investing Activities
Cash used in investing activities was $185 and $4,136 in the
three months 2026 and 2025. The three months 2026 included
cash paid for purchases of property, plant and equipment. The
three months 2025 included cash paid to acquire Inari and
purchases of property, plant and equipment partially offset by
proceeds from the sale of short-term investments. Refer to Note
7 to our Consolidated Financial Statements for further information
on acquisitions.
Financing Activities
Cash used in financing activities was $1,510 in the three months
2026 and cash provided by financing activities was $2,534 in the
three months 2025. In 2026, cash used was primarily driven by
repayments of $1,000 to pay off maturing unsecured notes as
described in Note 8 to our Consolidated Financial Statements
and dividend payments. Cash provided by 2025 was primarily
driven by proceeds from the issuance of various senior
unsecured notes which was partially offset by dividend payments.
Liquidity
Cash, cash equivalents, short-term investments and marketable
securities were $2,965 and $4,100 on March 31, 2026 and
December 31, 2025. Current assets exceeded current liabilities
by $7,023 and $6,961 on March 31, 2026 and December 31,
- We anticipate being able to support our short-term liquidity
and operating needs from a variety of sources including cash
from operations, commercial paper and existing credit lines.
We have raised funds in the capital markets and have accessed
the credit markets in the past and may continue to do so from
time-to-time. We continue to have strong investment-grade short-
term and long-term debt ratings that we believe should enable us
to refinance our debt as needed.
Our cash, cash equivalents, short-term investments and
marketable securities held in locations outside the United States
was 32% on March 31, 2026 compared to 20% on December 31,
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
There were no changes to our critical accounting policies and
estimates from those disclosed in our Annual Report on Form 10-
K for 2025, except as follows:
Following the reorganization discussed in Note 12 we will
continue to have two reportable segments, MedSurg and
Neurotechnology and Orthopaedics. The reorganization impacts
the composition of the Instruments and Joint Replacement
reporting units and results in a new reporting unit representing
the Ortho Tech business.
We assessed goodwill for impairment for the impacted reporting
units immediately before and after the reorganization and
concluded that there was no impairment of goodwill for any of the
reporting units impacted by the reorganization.
In connection with this reorganization we reallocated the goodwill
associated with the impacted businesses using the relative fair
value approach, resulting in a reallocation of $518 of goodwill
from the MedSurg and Neurotechnology segment to the
Orthopaedics segment.
Historical impairment assessments for our other reporting units
have indicated that their implied fair values exceed their
respective carrying amounts. We have not identified any factors
in 2026 that would lead us to believe that those reporting units
are at risk of a goodwill impairment.
Guarantees and Other Off-Balance Sheet Arrangements
We do not have guarantees or other off-balance sheet financing
arrangements, including variable interest entities, of a magnitude
that we believe could have a material impact on our financial
condition or liquidity.
| Dollar amounts are in millions except per share amounts or as otherwise specified. | 17 |
| STRYKER CORPORATION | 2026 First Quarter Form 10-Q |
OTHER MATTERS
Legal and Regulatory Matters
We are involved in various ongoing proceedings, legal actions
and claims arising in the normal course of our business, including
proceedings related to product, labor, tax, intellectual property
and other matters. Refer to Note 6 to our Consolidated Financial
Statements for further information.
FORWARD-LOOKING STATEMENTS
This report contains statements that are not historical facts and
are considered "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements are based on current projections about operations,
industry conditions, financial condition and liquidity. Words that
identify forward-looking statements include, without limitation,
words such as "may," "could," "will," "should," "possible," "plan,"
"predict," "forecast," "potential," "anticipate," "estimate," "expect,"
"project," "intend," "believe," "may impact," "on track," "goal,"
"strategy" and words and terms of similar substance used in
connection with any discussion of future operating or financial
performance, an acquisition or our businesses. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements. Those
statements are not guarantees and are subject to risks,
uncertainties and assumptions that are difficult to predict,
including uncertainties related to the impact of the cybersecurity
incident first reported on March 11, 2026 on our operations and
financial results. Therefore, actual results could differ materially
and adversely from these forward-looking statements, historical
experience or our present expectations. Some important factors
that could cause our actual results to differ from our expectations
in any forward-looking statements include the risks discussed in
Item 1A. "Risk Factors" of our Annual Report on Form 10-K for
- This Form 10-Q should be read in conjunction with our
Consolidated Financial Statements and accompanying notes to
our Consolidated Financial Statements in our Annual Report on
Form 10-K for 2025. While we believe that the assumptions
underlying such forward-looking statements are reasonable,
there can be no assurance that future events or developments
will not cause such statements to be inaccurate. All forward-
looking statements contained in this report are qualified in their
entirety by this cautionary statement. We expressly disclaim any
intention or obligation to publicly update or revise any forward-
looking statement to reflect any change in our expectations or in
events, conditions or circumstances on which those expectations
may be based, or that affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
Previous: Item 1. FINANCIAL STATEMENTS · Next: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK